Clinical Trial Update: Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial update for recombinant Factor IX product IB1001 in Hemophilia B completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• IB1001 (Recombinant Factor IX)

Snippet

Sponsor: Medexus Pharma, Inc. | Conditions: Hemophilia B | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-09-10